The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 11, 2025

Filed:

Sep. 06, 2019
Applicant:

Green Cross Corporation, Yongin-si, KR;

Inventors:

Min Jung Kim, Yongin-si, KR;

Geun Hye Yeo, Yongin-si, KR;

Haeng Eun Song, Yongin-si, KR;

Ji Yoon Park, Yongin-si, KR;

Yuna Kim, Yongin-si, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 1/16 (2006.01); C07K 1/22 (2006.01); C07K 1/34 (2006.01); C07K 1/36 (2006.01); C07K 16/38 (2006.01);
U.S. Cl.
CPC ...
C07K 16/38 (2013.01); C07K 1/165 (2013.01); C07K 1/22 (2013.01); C07K 1/34 (2013.01); C07K 1/36 (2013.01); C07K 2317/10 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.


Find Patent Forward Citations

Loading…